Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
None
Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

The aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment …

progesterone receptor
sentinel node
estrogen receptor
axillary lymph node dissection
breast cancer staging
  • 0 views
  • 20 Oct, 2021
  • 3 locations
None
Nivolumab Ipilimumab and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and …

growth factor
erbb2
mammogram
measurable disease
epidermal growth factor
  • 0 views
  • 25 Jan, 2021
  • 1 location
None
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

The purpose of study is to determine tolerability and safety profile of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer, and also to confirm the dose applicability to Japanese.

growth factor
estrogen receptor
estrogen
erbb2
epidermal growth factor
  • 0 views
  • 22 Oct, 2021
  • 2 locations
None
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

growth factor
estrogen receptor
estrogen
erbb2
mammogram
  • 13 views
  • 25 Jul, 2021
  • 12 locations
None
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen LHRHa) plus a CDK4/6 inhibitor, in women with HR+ and HER2- LABC or MBC. Primary endpoint: To assess the clinical …

bone metastases
fulvestrant
aromatase inhibitor
spiral computed tomography
liver metastasis
  • 1 views
  • 24 Jan, 2021
  • 15 locations
None
Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression

This is an open-label, single arm, multicenter phase II study evaluating treatment with pembrolizumab in combination with paclitaxel in patients with locally advanced or metastatic non-luminal Hormone receptor-positive, HER2-negative (hereafter referred to as HR+/HER2-) breast cancer who had recurrence or progression while receiving previous therapy with a CDK inhibitor in …

bone metastases
fulvestrant
erbb2
aromatase inhibitor
paclitaxel
  • 0 views
  • 01 Aug, 2021
  • 5 locations
None
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)

The goal of this study is to evaluate the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in participants with unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with taxane anti-cancer agent, trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1). The primary hypothesis is …

growth factor
breast carcinoma
her2/neu-positive breast cancer
erbb2
mammogram
  • 0 views
  • 22 Oct, 2021
  • 15 locations
None
  • 0 views
  • 15 Oct, 2021
  • 5 locations
None
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2

progesterone receptor
growth factor
estrogen receptor
estrogen
erbb2
  • 0 views
  • 02 Aug, 2021
  • 1 location
None
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the efficacy and safety of fulvestrant or capecitabine as maintenance therapy after first-line chemotherapy in hormone receptor-positive, human epidermal

fulvestrant
erbb2
cancer chemotherapy
liver metastasis
kidney function tests
  • 1 views
  • 26 Jan, 2021
  • 7 locations